Braftovi (encorafenib) is an oral targeted therapy used to treat adults with cancers that have a specific genetic mutation called BRAF V600E. It belongs to a class of drugs known as BRAF inhibitors, which block the activity of the abnormal BRAF protein that promotes uncontrolled cancer cell growth.

Indications:

• Unresectable or metastatic melanoma with BRAF V600E or V600K mutation (in combination with Mektovi [binimetinib], a MEK inhibitor)

• Metastatic colorectal cancer with BRAF V600E mutation (in combination with Erbitux [cetuximab], an EGFR inhibitor)

How it works:

• Braftovi inhibits the mutated BRAF kinase, a protein involved in the MAPK/ERK signaling pathway, which is overactive in certain cancers.

• Blocking BRAF slows or stops cancer cell growth and may shrink tumors.

Administration:

• Oral capsules, taken once daily.

• Always used in combination with other drugs to improve efficacy and reduce resistance.

Common side effects:

• Fatigue

• Nausea

• Joint pain

• Skin rash

• Abdominal pain

Serious risks:

• Risk of new skin cancers (monitoring required)

• Liver problems

• Heart rhythm issues (QT prolongation)

• Eye disorders

Patients must undergo genetic testing to confirm the presence of a BRAF V600E mutation before starting treatment.